On Monday, September 9, the Council for Innovation Promotion hosted an important briefing on the U.S. Patent and Trademark Office’s recently released Drug Patent and Exclusivity Study.
The study, requested by Senator Thom Tillis (R-NC), investigated the relationship between patents and market exclusivity for a sample of FDA-approved drugs, finding that patent expiration alone did not determine when generic competitors entered the market.
The briefing touched on the study’s findings, as well as fact-based policy solutions for promoting drug competition and innovation.
You can read a summary of the USPTO Drug Patent and Exclusivity Report here and find the full recording of the event and photos below!
Distinguished Guests and Panelists
Emily Michiko Morris
- David L. Brennan Endowed Chair, Associate Professor, and Associate Director of the Center for Intellectual Property Law & Technology, University of Akron School of Law
Jamie Simpson
- Chief Policy Officer and Counsel, Council for Innovation Promotion (C4IP)
Corey Salsberg
- Vice President and Global Head of IP Affairs, Novartis
Frank Cullen (moderator)
- Executive Director, Council for Innovation Promotion (C4IP)